- By ICR Secretariat
- Posted Tuesday, November 15, 2022
Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease
With an FDA approval 19 months ago to treat chronic kidney disease, AstraZeneca’s Farxiga dominated the race against its primary SGLT2 rival—Eli Lilly and Boehringer Ingelheim’s Jardiance. And since then, AZ has reaped the rewards as Farxiga has produced hefty sales increases.